Trial Profile

A Phase III, Randomized Study of Bevacizumab and Paclitaxel in Combination with Atezolizumab As a Treatment for Patients with Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab; Paclitaxel
Indications Advanced breast cancer; Cancer metastases; Early breast cancer; HER2 negative breast cancer; Liver metastases; Male breast cancer
Focus Therapeutic Use
Acronyms AMBITION

14 Nov 2023 Planned End Date changed from 30 Jun 2025 to 30 Sep 2025.
14 Nov 2023 Planned primary completion date changed from 30 Jun 2025 to 30 Sep 2025.
14 Nov 2023 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com